Author + information
- Received December 26, 2018
- Revision received February 27, 2019
- Accepted March 5, 2019
- Published online May 13, 2019.
- Dhaval Kolte, MD, PhDa,
- Sahil A. Parikh, MDb,
- Gregory Piazza, MD, MSc,
- Mehdi H. Shishehbor, DO, PhDd,
- Joshua A. Beckman, MD, MSe,
- Christopher J. White, MDf,
- Michael R. Jaff, DOg,
- Alexander Iribarne, MD, MSh,
- Tom C. Nguyen, MDi,
- James B. Froehlich, MD, MPHj,
- Kenneth Rosenfield, MDk,
- Herbert D. Aronow, MD, MPHa,∗ (, )@herbaronowMD,
- ACC Peripheral Vascular Disease Council
- aDivision of Cardiology, Warren Alpert Medical School of Brown University, Providence, Rhode Island
- bDivision of Cardiology, New York-Presbyterian Hospital, Columbia University Medical Center, New York, New York
- cDivision of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
- dDivision of Cardiovascular Medicine, University Hospitals, Case Western Reserve University, Cleveland, Ohio
- eDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
- fDepartment of Cardiovascular Diseases, Ochsner Medical Center, New Orleans, Louisiana
- gDivision of Cardiology, Newton-Wellesley Hospital, Newton, Massachusetts
- hDepartment of Surgery, Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
- iDepartment of Cardiothoracic and Vascular Surgery, Memorial Hermann Hospital, University of Texas Health Science Center, Houston, Texas
- jDivision of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan
- kDivision of Cardiology, Massachusetts General Hospital, Boston, Massachusetts
- ↵∗Address for correspondence:
Dr. Herbert D. Aronow, Lifespan Cardiovascular Institute, Warren Alpert Medical School of Brown University, 593 Eddy Street, RIH APC 730, Providence, Rhode Island 02903.
• The success of the heart team could serve as a model for the efficient and effective management of patients with peripheral vascular disease.
• A multidisciplinary “vascular team” approach should be used for the treatment of CLI, PE, AIS, and acute aortic syndromes.
• Prospective evaluation is warranted to determine how to best integrate this approach into routine clinical care.
Peripheral vascular disease affects millions of individuals worldwide, and results in significant morbidity and mortality. The complex nature of the disease, the presence of multiple comorbidities, and the existence of a wide variety of therapeutic options suggests that a multidisciplinary approach to treatment has the potential to improve care of these patients. The success of the heart team for complex coronary artery and structural heart disease could serve as a model for the efficient and effective management of patients with peripheral vascular disease. In this paper, the authors propose a multidisciplinary vascular team approach for the treatment of critical limb ischemia, pulmonary embolism, acute ischemic stroke, and acute aortic syndromes. The successful implementation of such vascular teams has the potential to significantly enhance quality of care, improve clinical outcomes, and reduce costs. Prospective evaluation is warranted to determine how to best integrate this approach into routine clinical care.
- aortic dissection
- critical limb ischemia
- multidisciplinary team
- peripheral artery disease
- pulmonary embolism
The views expressed in this paper by the American College of Cardiology's (ACC's) Peripheral Vascular Disease Council do not necessarily reflect the views of the Journal of the American College of Cardiology or the ACC.
Dr. Parikh has served on the advisory board of Abbott Vascular, Boston Scientific, Medtronic, Cardiovascular Systems, Inc., and Philips; and has served as a consultant for Terumo and Asahi. Dr. Piazza has received grant support from Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, British Technology Group Ltd./Ekosonic Endovascular System, Bayer, and Portola. Dr. Beckman has served as a consultant for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novo Nordisk, and Sanofi; and has served on the Data Safety and Monitoring Board of Bayer and Novartis. Dr. Jaff has served as a noncompensated advisor to Abbott Vascular and Boston Scientific; has served as a consultant to Medtronic, Philips/Volcano, Biotronik, and British Technology Group Ltd.; and is an equity investor in Embolitech, eFemoral, Vascular Therapies, and Gemini. Dr. Nguyen has served as a consultant for Edwards Lifesciences, Abbott, and LivaNova. Dr. Froehlich has served as a consultant for Pfizer, Janssen, Merck, Boehringer Ingelheim, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.
- Received December 26, 2018.
- Revision received February 27, 2019.
- Accepted March 5, 2019.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.